TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32400903
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) adapted for SE-AN
Study: 35723225
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (metformin/pioglitazone/exenatide)
Study: 33571026
Drug: Ginkgolide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgolide plus aspirin
Study: 32988524
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 3 ppm Cx and 34.5 μg 25-OH-D3
Study: 32988524
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 6 ppm Cx and 69 μg 25-OH-D3
Study: 32988524
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 9 ppm Cx and 103.5 μg 25-OH-D3
Study: 32988524
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 12 ppm Cx and 138 μg 25-OH-D3
Study: 39466236
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily for 8 weeks
Study: 35830338
Drug: Low-Intensity Shock
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Shock Wave Therapy (LiST)
Study: 32085823
Drug: ART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART plus vorinostat and T-cell inducing vaccines (ART + V + V)
Study: 32475440
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g C. lanatus essential oil/kg feed (1gCL)
Study: 32475440
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g C. lanatus essential oil/kg feed (2gCL)
Study: 35322637
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (basic treatment, Qiming granules, individualized Chinese herbal medicines)
Study: 35322637
Drug: Stationary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stationary treatment (basic treatment and Qiming granules)
Study: 32880495
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg twice a day) in combination with docetaxel
Study: 32880495
Drug: Selumetinib (monotherapy)
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib (monotherapy)
Study: 32880495
Drug: Selumetinib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (in combination with docetaxel)
Study: 33610365
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (combination of 4 drugs: ACE inhibitor or ARB, beta-blocker, statin, and 1 antiplatelet drug)
Study: 33610365
Drug: Coronary artery
Normalized name: Drug-coated coronary artery stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary artery bypass grafting with medical therapy
Study: 34432302
Drug: PAS-calcium formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS-calcium formulation (PAS-Ca)
Study: 33256420
Drug: Endoscopic tattooing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic tattooing with two injection points and 1 ml of labeling volume
Study: 33256420
Drug: Endoscopic tattooing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic tattooing with three injection points and 1.5 ml of labeling volume
Study: 33256420
Drug: Endoscopic tattooing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic tattooing with two injection points and 1.5 ml of labeling volume
Study: 33256420
Drug: Endoscopic tattooing
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic tattooing with three injection points and 1 ml of labeling volume
Study: 32230754
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVOO), 50 mL daily for 3 weeks
Study: 32230754
Drug: Refined olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined olive oil (ROO), 50 mL daily for 3 weeks
Study: 36227782
Drug: Linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 290 μg
Study: 33851518
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg daily for a week
Study: 33851518
Drug: Rifampicin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin treatment
Study: 32333325
Drug: Selonsertib (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib (1, 3, 10, 30, or 100 mg)
Study: 32333325
Drug: Selonsertib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selonsertib (various doses)
Study: 32195961
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the soft palate and tongue base, 8 seconds per point, twice a week for 2 months using Therapy Plus NS 13678 Laser.
Study: 34370681
Drug: Topical treatments
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatments for oral mucositis as per Mucositis Guidelines
Study: 35717342
Drug: NaPB 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaPB 4.8 g/m²/day
Study: 33336219
Drug: Lemborexant 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 2.5 mg
Study: 33336219
Drug: Lemborexant 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 15 mg
Study: 36412916
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (three 30-minute sessions weekly during chemotherapy)
Study: 36412916
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard breast cancer treatment without yoga)
Study: 33045913
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol + micronised progesterone
Study: 33045913
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol + medroxyprogesterone acetate
Study: 32629446
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by cetuximab and RT (IBRT)
Study: 32629446
Drug: Cisplatin concurrent
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin concurrent with RT (CRT)
Study: 34077270
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg IV every 3 weeks for 17 cycles
Study: 34077270
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus trastuzumab (TH) 80 mg/m2 IV with H once every week for 12 weeks followed by H for 39 weeks
Study: 33581997
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment with water resistance therapy (WRT) plus vocal hygiene program (n = 12)
Study: 33649930
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxorubicin (group A)
Study: 33649930
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg doxorubicin (group B)
Study: 32106110
Drug: Blocking GDF15
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking GDF15 with a neutralizing antibody
Study: 35256489
Drug: Low-flow anesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anesthesia (1 L.min‐1 after initial 6 L.min‐1 for 10 minutes)
Study: 35256489
Drug: Mid-flow anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-flow anesthesia (2 L.min‐1)
Study: 35256489
Drug: High-flow anesthesia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow anesthesia (4 L.min‐1)
Study: 33594772
Drug: GI-6301 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI-6301 vaccine (80 × 10^7 yeast cells)
Study: 32268771
Drug: Group D1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D1: perineural administration of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Study: 32268771
Drug: Group D2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D2: intravenous infusion of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Study: 34617341
Drug: Implant-level (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-level (IL) connection
Study: 33544240
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg once daily for 40 weeks
Study: 35710320
Drug: Clemastine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (active treatment), n=53, geometric mean=6.33 pg/mL
Study: 35710320
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, n=73, geometric mean=7.00 pg/mL
Study: 35710320
Drug: Clemastine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (active treatment)
Study: 33249609
Drug: Full prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full prophylaxis (palivizumab doses for each month of RSV exposure)
Study: 33251697
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (IGlu)
Study: 33461782
Drug: Pazopanib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 600 mg
Study: 35764956
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy plus PD‐1 antibody with preoperative chemoradiation (Arm A)
Study: 35764956
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy plus PD‐1 antibody without preoperative chemoradiation (Arm B)
Study: 34525285
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide typhoid conjugate vaccine (Vi-TCV)
Study: 38281499
Drug: Meningococcal capsular
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal capsular group A conjugate (MenA) vaccine
Study: 32926834
Drug: Co-administered Na-GST-1
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered Na-GST-1 and Na-APR-1 (M74) vaccines (30 μg or 100 μg of each), adjuvanted with Alhydrogel and glucopyranosyl lipid A, administered intramuscularly on days 0, 28, and 180.
Study: 32926834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received hepatitis B vaccine plus saline, administered intramuscularly on days 0, 28, and 180.
Study: 33264544
Drug: Chemotherapy (5-fluorouracil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab every 2 weeks)
Study: 33143212
Drug: Phaseolus Vulgaris
Normalized name: PHASEOLUS VULGARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phaseolus Vulgaris (PV) consumption, 250 g as an extract thrice weekly for 6 weeks
Study: 32698634
Drug: Triphala (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphala (1 g standardized as 91.82 ± 0.5 mg gallic acid, administered BID)
Study: 32698634
Drug: Placebo (wheat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (wheat flour, administered BID)
Study: 33900931
Drug: cCBT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: cCBT + treatment as usual (TAU)
Study: 33845941
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural steroid injection
Study: 33115285
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg/2 weeks after 160 mg initial dose)
Study: 33115285
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks)
Study: 35929973
Drug: Investigational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational treatment arm
Study: 32439266
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of GAA for 4 weeks
Study: 34289222
Drug: Mebeverine 200
Normalized name: mebeverine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 200 mg once a day for 3 months
Study: 35831045
Drug: Oral pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pravastatin
Study: 32650673
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for vulvodynia
Study: 34192922
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional oral regime for 24 hours postoperatively
Study: 34192922
Drug: Only intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intraoperative dose of TXA
Study: 35317789
Drug: Automated Treatment
Normalized name: Automated peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated Treatment (AT), n=250, consisting of a fully-automated smartphone-based intervention with 10 weeks of nicotine replacement therapy (NRT) including transdermal patches and lozenges.
Study: 35317789
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST), n=250, connected to the Florida Quitline for telephone-based treatment and receiving a 10-week supply of nicotine replacement therapy (NRT).
Study: 36228777
Drug: Medication first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication first arm (n = 226)
Study: 34089546
Drug: Agomelatine (25–50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25–50 mg) with a guided sleep phase advance
Study: 82282326
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 250 to 300 mg/d
Study: 82282326
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 500 to 600 mg/d
Study: 82282326
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 900 to 1000 mg/d
Study: 82282326
Drug: Ursodeoxycholic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid, 10 to 12 mg/kg body weight
Study: 38291017
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatment
Study: 36107505
Drug: Turmeric-boswellia formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric-boswellia formulation (TBF) 1000 mg
Study: 33025648
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg KLH immunization
Study: 33025648
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg KLH intradermal administration after immunization
Study: 35465983
Drug: H7N9 IIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later (Group 1)
Study: 35465983
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of H7N9 IIV at three-week intervals after IIV4 alone (Group 2)
Study: 35465983
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of IIV4 (Group 3)
Study: 37369826
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg/day)
Study: 35241360
Drug: Over-the-counter diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter diet pills
Study: 33645377
Drug: Test 1
Normalized name: Bar Test 10% Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 1 (0.413/0.050 mg/day E3/TMG)
Study: 33645377
Drug: Test 2
Normalized name: Methitest 25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 2 (0.311/0.090 mg/day E3/TMG)
Study: 33645377
Drug: Test 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 3 (0.209/0.137 mg/day E3/TMG)
Study: 33907099
Drug: XELOX (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (capecitabine 1,000 mg/m2; twice daily for 14 days with oxaliplatin 130 mg/m2 on day 1, every 21 days)
Study: 33907099
Drug: DX (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX (capecitabine 1,000 mg/m2; twice daily for 14 days with docetaxel 75 mg/m2 on day 1, every 21 days)
Study: 35658487
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice a day
Study: 34013747
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg body wt‐1)
Study: 34013747
Drug: Caffeine +
Normalized name: Voost Energy Caffeine + B Vitamin Complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine + Acetaminophen (Caffeine 5 mg·kg body wt‐1 + Acetaminophen 1,500 mg)
Study: 34013747
Drug: Acetaminophen (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,500 mg)
Study: 35414203
Drug: Tablet-based fatigue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based fatigue education and prescription program (FatigueUCope)
Study: 36370124
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control treatment)
Study: 34102418
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (1 Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training
Study: 34102418
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS combined with daily gait training
Study: 32114477
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) plus metformin
Study: 35492335
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg, 3 times daily for 5 days)
Study: 34728434
Drug: Suture button
Normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture button suspension (SBS)
Study: 34997835
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg
Study: 33587674
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment in LipiFlow-surgery eye
Study: 33587674
Drug: LipiFlow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LipiFlow treatment in LipiFlow-nonsurgery eye
Study: 32604430
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (30 minutes daily)
Study: 1994041002
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 250 mg twice a day
Study: 35358154
Drug: 2-g bolus
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-g bolus of tranexamic acid (TXA)
Study: 35358154
Drug: 1-g bolus
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-g bolus plus 1-g infusion of tranexamic acid (TXA) over 8 hours
Study: 33629488
Drug: Topical eflornithine
Normalized name: eflornithine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eflornithine cream twice daily for 16 weeks
Study: 33629488
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical eflornithine cream and long‐pulsed Nd‐YAG laser for 16 weeks
Study: 32135143
Drug: Expedited partner
Normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expedited partner therapy prescription received
Study: 32135143
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to dispense expedited partner therapy prescription
Study: 32135143
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of azithromycin 1000 mg for treatment of chlamydia
Study: 32135143
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of cefixime 400 mg for treatment of gonorrhea
Study: 616774609
Drug: Abdominal application
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal application of traditional Chinese medicine combined with chewing gum
Study: 616774609
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and nursing care (Control)
Study: 32543120
Drug: Edaravone 60
Normalized name: edaravone 60 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 60 mg (therapeutic dose)
Study: 32543120
Drug: Edaravone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 300 mg (supratherapeutic dose)
Study: 35618299
Drug: Physical education
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical education intervention program (three 10-minute weekly medium- to high-intensity activities for one academic year)